Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

584 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection.
Waldenström J, Westin J, Nyström K, Christensen P, Dalgard O, Färkkilä M, Lindahl K, Nilsson S, Norkrans G, Krarup H, Norrgren H, Rauning Buhl M, Stenmark S, Lagging M. Waldenström J, et al. Among authors: farkkila m. PLoS One. 2016 May 11;11(5):e0155142. doi: 10.1371/journal.pone.0155142. eCollection 2016. PLoS One. 2016. PMID: 27167219 Free PMC article. Clinical Trial.
Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Christensen P, Leutscher P, Norkrans G; NORDynamIC Study Group. Lagging M, et al. Among authors: farkkila m. Hepatology. 2008 Aug;48(2):695. doi: 10.1002/hep.22450. Hepatology. 2008. PMID: 18666232 No abstract available.
Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection.
Pedersen C, Alsiö Å, Lagging M, Langeland N, Färkkilä M, Buhl MR, Mørch K, Westin J, Sangfelt P, Norkrans G, Christensen PB; NORDynamicIC Study Group. Pedersen C, et al. Among authors: farkkila m. J Viral Hepat. 2011 Apr;18(4):245-51. doi: 10.1111/j.1365-2893.2010.01303.x. J Viral Hepat. 2011. PMID: 20384961 Clinical Trial.
Hepatitis C treatment response kinetics and impact of baseline predictors.
Lindh M, Arnholm B, Eilard A, Färkkilä M, Hellstrand K, Lagging M, Langeland N, Mørch K, Nilsson S, Pedersen C, Buhl MR, Wahlberg T, Wejstål R, Westin J, Norkrans G. Lindh M, et al. Among authors: farkkila m. J Viral Hepat. 2011 Jun;18(6):400-7. doi: 10.1111/j.1365-2893.2010.01323.x. J Viral Hepat. 2011. PMID: 20500548
Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.
Alsiö A, Jannesson A, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Westin J, Hellstrand K, Norkrans G, Lagging M; NORDynamIC Study Group. Alsiö A, et al. Among authors: farkkila m. Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1631-5. doi: 10.1007/s10096-011-1486-5. Epub 2011 Nov 24. Eur J Clin Microbiol Infect Dis. 2012. PMID: 22113307
584 results